News|Articles|December 2, 2025

2025 in Hepatology: New MASLD Therapies, HBV Updates, and More

Author(s)Hersh Shroff, MD, MPA, Zobair Younossi, MD, MPH, Wei Zhang, MD, PhD

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

2025 has marked a clear turning point in hepatology, bringing advances that are reshaping both the scientific landscape and everyday clinical practice. After years defined by limited therapeutic options and slow-moving pipelines, this year delivered transformative progress, from the long-awaited arrival of effective pharmacologic treatments for MASLD/MASH to renewed innovation in viral hepatitis, cholestatic liver diseases, portal hypertension, and alcohol-associated liver disease.

Related to this article

November 7th, 2026

Bepirovirsen Functional Cure Durable Through Week 96 in Chronic Hepatitis B

End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.

November 7th, 2026

Survodutide Improves MASH Liver Endpoints Across Weight Loss Categories

Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.

November 6th, 2026

Saroglitazar Resolves MASH Without Fibrosis Worsening: EVIDENCES X

In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.

November 6th, 2026

Semaglutide Linked to Lower Liver Enzymes, Weight in Real-World MASH Data

Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.

November 6th, 2026

Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study

Once-monthly efimosfermin alfa reduced liver stiffness, ELF, and PRO-C3 through 52 weeks in MASH with F2–F4 fibrosis, including compensated cirrhosis.

November 5th, 2026

Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG

In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.

November 5th, 2026

Itch Relief With Volixibat Tied to Better Sleep, Fatigue in PSC

In the phase 2b VISTAS trial, volixibat improved sleep vs placebo in PSC with cholestatic pruritus, and itch responders saw greater fatigue and sleep gains.

November 5th, 2026

ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC

In the phase 3 ELSPIRE trial, 85.3% of patients with PBC and ALP below 1.67× ULN reached ALP normalization on elafibranor at 52 weeks vs 23.3% on placebo.